阿加曲班治疗急性缺血性脑卒中疗效及应用时机的临床研究  

Clinical research of Argatroban in treating acute ischemic stroke in different phase

作　　者：赵智江[1,2] 张微微[1] 赵秀欣[1] 范慧敏[1] 刘楠[1] 

机构地区：[1]北京军区总医院神经内科,100700 [2]山西医科大学

出　　处：《中华老年心脑血管病杂志》2012年第2期181-182,共2页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的观察急性缺血性脑卒中后不同时间段应用阿加曲班的临床疗效。方法随机选取我院发病24h内的急性缺血性脑卒中患者80例,根据发病6～12h和13～24h 2个时间段应用阿加曲班,将患者分为A组28例,B组52例。7d后进行美国国立卫生研究院脑卒中量表(NIHSS)评分,以判定临床疗效。结果与治疗前比较,2组治疗后NIHSS评分明显降低,差异有统计学意义(P<0.05)。2组临床疗效比较差异无统计学意义(P>0.05)。结论阿加曲班治疗急性缺血性脑卒中有临床疗效。发病24h内不同时间应用对临床疗效无影响。Objective To compare the clinical efficacy of Argatroban in treating acute ischemic stroke in different phase. Methods 80 patients with acute ischemic stroke were recruited and ana- lyzed randomly within 48 hours of onset. First,intravenous Argatroban was observed for 7 days after the NIHSS score. The patients were divided into A group（6-12 h,n=28） ,B group（13--24 h, n= 52）. NIHSS scores were compared between test and control groups after the treatment for 7 days. Results There were statistically significant difference between pre- and post-treatment within the each group,P〈0.05. The difference was not statistically significant between A and B group,P〉0.05. Conclusion Argatroban could improve the prognosis of patients with acute ischemic stroke and there is no effect on clinical efficacy using Argatroban in different phase within 24 h onset of acute ischemic stroke.

关 键 词：脑缺血 卒中 凝血酶 组织型纤溶酶原激活物 抗凝药 血栓形成 

分 类 号：R743.3[医药卫生—神经病学与精神病学]